Sedatives I and II Flashcards
1. List the principal criteria for the appropriate use of sedative-hypnotic/anxiolytic agents. 2. List the prototype barbiturates, benzodiazepines, and GABAA-alpha1 selective agonists, describe their clinical uses, their mechanism and site of action, and how their pharmacokinetic differences provide the basis for selection of which agent to use and for what purpose. 3. List the major side effects and abuse potential of the prototype barbiturates, benzodiazepines, and GABAA-alpha1 selective ago
Standard reasons to treat anxiety w/drugs
1) anxiety
2) not for 8 hours of sleep
3) when it affects quality of life
MOA of Barbiturates
not really known, but seem to be GABAA agonist
Long acting barbo class
phenobarbital
phenobarbital t 1/2
80-120 hrs
pentobarb t 1/2
15-48 hrs
intermediate acting barbo
pentobarbital
short acting barbo
thiopental
clincal use for barbos
induction in general anesthesia and seziure disorders
old use for barbos
insomnia/anxiety
CNS activity of barbos
sedation to coma/death
state resembaling natural sleep
anticonvulsant
sx of barbo OD
comatose
bradypnea
marked hypotension
weak rapid pulse
TX for barbo OD
ABC rule out narcotics gastric lavage bicarb hemodialysis
ways tolerence to barbos comes about
induction of P450
cross-tolerence to all CNS depressents
drug class with potentially life-threatening dependance
barbos
early stages of barbo withdrawal sx
weakness, trembling, insomnia, and abdominal cramps
reversal of early stage barbo withdrawal
CNS depressant
when can barbo withdrawal be reversed
early only
sx of late stage barbo withdrawal
orthostatic hypotension, delirium, convilsions leading to status elipepticus
lenght of barbo withdrawl
7-9 days
contraindications of barbos
pts with hx or fam hx of acute intermittent porphyria
DOC class for anxiety
benzos
DOC for rapid treatment of panic attacks
benzos
prototype benzo
diazempam
CNS activity of benzos
sedative/hypnotic anxiolytic anticonvulsant muscle relaxant amnestic
anti anxiety that does not induce P450
benzo
advantages of benzos
safety, no induction of P450, mild withdrawal
MOA of benzo
binds GABAA receptor, increases CL- channel increasing frenquency of openings and release of GABA throughout CNS
GABA receptor that benzos bind to
alpha 1,2,3,and 5
GABA receptor mediating sedative properties of benzo
a 1, possibly 3
GABA receptor mediating anxiolytic properties of benzo
a2, possibly 3
GABA receptor mediating anticonvulsant properties of benzo
a3, possibly 1
GABA receptor mediating muscle relaxant properties of benzo
a2
benzo antagonist
flumazenil